Disease Focus
Oncology
Auto-immune
Mechanism
Gene location/fusion protein
Driver mutations
Target overexpression
Synthetic lethality
Clinical Impact
Address tumors with specific genetic mutations
Sensitize cancers to standard of care
Overcome resistance
Benefits
First-in-class/innovator status
Fast-track/breakthrough potential
Rapid path to patients and value
Differentiated portfolio advancing towards Phase 1: multiple pre-clinical programs against validated targets considered intractable by conventional discovery approaches